2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo
2007
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis
Treggiari MM, Rosenfeld M, Retsch‐Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatric Pulmonology 2007, 42: 751-756. PMID: 17647287, DOI: 10.1002/ppul.20665.Peer-Reviewed Original ResearchConceptsAnti-pseudomonal antibioticsCystic fibrosisEarly interventionInitial Pseudomonas aeruginosa infectionSafe treatment regimenObstructive lung diseasePseudomonas aeruginosa infectionChronic endobronchial infectionLower airwaysTreatment regimenEndobronchial infectionClinical benefitLarge trialsLung diseaseAeruginosa infectionPA isolatesYoung childrenPa acquisitionFibrosisInfectionChildrenPrimary causePseudomonas aeruginosaWindow of opportunityEradication